Kivu: Advancing safer ADCs against established targets

With backing from Novo Ventures, a pharma veteran as COO, and a pair of preclinical antibody-drug conjugates, Kivu Bioscience is putting the non-core asset spinout model to the test. It’s also on a mission to elevate tolerability as a priority for the next-generation of ADCs.

The biotech was launched with a license to two antibody-drug conjugates that were constructed using the GlycoConnect site-specific conjugation technology of Synaffix B.V., then spun out last year when Synaffix was acquired by Lonza Group Ltd. (SIX:LONN)...